OXFORD Gene Technology, the molecular genetics company, has announced that Dr John Anson has taken over as CEO from Dr Mike Evans, who has become a non-executive director of the board.

Dr Evans has been with the company since 2005 during which time he spearheaded OGT’s transformation from a microarray licensing-led business model to a successful molecular genetics products business.

Dr Anson has been responsible for OGT’s successful alignment with market growth in molecular genetics and the move towards molecular diagnostics. He said: “I am looking forward to picking up the mantle from Mike to steer OGT in its next growth phase.”